Bayer has stopped marketing Nimotop (nimodipine capsules) due to reduced market demand and the availability of generic alternatives. Orders to wholesalers were ceased at the end of October based on product expiration dates.

Nimotop is indicated for the treatment of subarachnoid hemorrhage (SAH).

For more information call (877) 229-3750 or visit http://www.fda.gov/cder/drug/shortages/discontinuation.pdf.